Eicosanoids & Vascular Pharmacology

Human vascular tissue research
Welcome to our homepage, enjoy your visit!

This website is certified by Health On the Net Foundation. Click to verify.

Host laboratory for BA, Master and PhD Thesis, contact: xnorel@hotmail.com,  INSERM U1148, Laboratory for Vascular Translational Science (LVTS). CHU X. Bichat, 46, rue Henri Huchard, 75877 Paris Cedex 18, France. Access, map. Tel: 33 1 40 25 75 29, Fax: 33 1 40 25 86 02.
We comply with the HONcode standard for trustworthy health information: verify here. Webmaster: X. Norel (PhD). ©2018-2021 Eicosanoids & Vasc. Pharmacol. about the website
Last update: 14/06/18

Laboratory & Links
 


Bibliography

Last update : 14/06/18
 

Publications of the laboratory (1990 to present) concerning the eicosanoids

Eicosanoids
  1. Norel, X., Labat, C., Gardiner, P. and Brink, C. Prostanoid contractions in human isolated pulmonary muscle preparations : inhibition by BAY u3405. Adv. Prostaglandin, Thromboxane and Leukotriene Research., 21: 473-476, 1990.
  2. Norel, X., Labat, C., Gardiner, P. and Brink, C. Inhibitory effects of BAY u3405 on prostanoid-induced contractions of human isolated pulmonary muscle preparations. Br. J. Pharmacol. 104 : 591-595, 1991.
  3. Labat, C.,Ortiz, J.L., Norel, X., Gorenne, I., Verley, J., Abram, T.S., Cuthbert, N.J., Tudhope, S.R., Norman, P., Gardiner, P. and Brink, C. A second cysteinyl leukotriene receptor in human lung. J. Pharmacol. Exp. Ther. 263: 800-805, 1992.
  4. Gorenne, I, Labat, C., Gascard, J.P., Norel, X., Muller-Peddinghaus R., Mohrs, K.H., Taylor, W.A. Gardiner, P.J. and Brink, C. (R)-2-[4-(Quinolin-2-yl-methoxy) phenyl-2- cyclopentyl acetic acid] (Bay x1005) a potent leukotriene synthesis inhibitor: effects on anti-IgE challenge in human airways. J. Pharmacol. Exp. Ther. 268: 868-872, 1994.
  5. Gardiner, P.J., Abram, T.S., Tudhope, S.R., Cuthbert, N.J., Norman, P. and Brink, C. Leukotriene receptors and their selective antagonists. Adv. Prostaglandin, Thromboxane and Leukotriene Research. 22: 49-61, 1994.
  6. Gorenne, I., Ortiz, J.L., Labat; C., Abram, T., Tudhope, S., Cuthbert, N., Norman, P., Gardiner, P., Morcillo, E. and Brink, C. Antagonism of leukotriene response in human airways by BAY x7195. Eur. J. Pharmacol. 275: 207-212, 1995.
  7. Ortiz, J.L. Gorenne, I., Cortijo, J., Seller, A. Labat, C., Saria, B., Abram, T.S. Gardiner, P.J., Morcillo, E. and Brink, C. Leukotriene receptors on human pulmonary endothelium. Br. J. Pharmacol. 115: 1382-1386, 1995.
  8. Gorenne, I., Sosse Alaoui, H., Gascard, J.P., Labat, C., Norel, X., De Montpreville, V.T. and Brink, C. Leukotriene synthesis inhibition during anti-IgE challenge of human lung parenchyma. Life Sciences. 59: 213-219, 1996.
  9. Gorenne, I., Norel, X. and Brink, C. Cysteinyl leukotriene receptors in the human lung: what's new? Trends Pharmacol. Sci. 17: 342-345, 1996.
  10. Gorenne, I., Norel, X. and Brink, C. More on the classification of cysteinyl leukotriene receptors. Trends Pharmacol. Sci. 18: 148-149, 1997.
  11. Serraf, A., Gascard, J.P., Bruniaux, J., Labat, C., Planche, C. and Brink, C. Pulmonary hypertension in infants with congenital heart defects: are leukotrienes involved? Mediators of Inflammation, 6: 323-326, 1997.
  12. Gorenne, I., Labat, C., Gascard, J.P., Norel, X., Nashashibi, N. and Brink, C. Leukotriene D4 contractions in human airways are blocked by SK&F 96365, an inhibitor of receptor-mediated calcium entry. J. Pharmacol. Exp. Ther. 284: 549-552,1998.
  13. Calvet JH, Gascard JP, Delamanche S, Brink C. Airway epithelial damage and release of inflammatory mediators in human lung parenchyma after sulfur mustard exposure. Hum Exp Toxicol., 18(2):77-81, 1999.
  14. Gorenne I, Labat C, Norel X, Gascard JP, Brink C. Cysteinyl-leukotrienes and the human lung. Adv Exp Med Biol., 447:171-9, 1999.
  15. Walch L., Labat C., Gascard J.P., de Montpreville V., Brink C. & Norel X. Prostanoid receptors involved in the relaxation of human pulmonary vessels. Br. J. Pharmacol., 126 (4), 859-866, 1999.
  16. Walch L, Norel X, Gascard JP, Brink C. Cysteinyl-leukotriene receptors in pulmonary vessels. J Physiol Pharmacol. 50(4):567-73, 1999.
  17. Gascard JP, Brink C. LTE4 blood levels in infants with congenital heart lesions. Adv Exp Med Biol., 469:307-11, 1999.
  18. Norel X., Walch L., Labat C., Gascard J.P., Dulmet E. & Brink C. Prostanoid receptors involved in the relaxation of human bronchial preparations. Br. J. Pharmacol., 126 (4), 867-872, 1999.
  19. Walch L., Norel X., Gascard J.P. & Brink C. Functional studies of leukotriene receptors in vascular tissues. Am. J. Respir. Crit. Care Med. 161(2): S107-S111, 2000.
  20. Bäck M, Norel X, Walch L, Gascard J, de Montpreville V, Dahlen S, Brink C. Prostacyclin modulation of contractions of the human pulmonary artery by cysteinyl-leukotrienes. Eur J Pharmacol., 401(3):389-395,2000.
  21. Bäck M, Norel X, Walch L, Gascard J, Mazmanian G, Dahlen S, Brink C. Antagonist resistant contractions of the porcine pulmonary artery by cysteinyl-leukotrienes. Eur J Pharmacol., 401(3):381-388, 2000.
  22. Walch L., Brink C. & Norel X. The muscarinic receptor subtypes in human blood vessels.
    Therapie. 56(3):223-6, 2001.
  23. Walch L., de Montpreville V., Brink C. & Norel X. Prostanoid EP1- and TP- receptors involved in the contraction of human pulmonary veins. Br. J. Pharmacol. 134(8):1671-1678, 2001.
  24. Bäck M., Walch L., Norel X., Gascard J-P., Mazmanian G. & Brink C. Modulation of vascular tone and reactivity by nitric oxide in porcine pulmonary arteries and veins. Acta Physiol. Scand., 174:9-15, 2002.
  25. Walch L., Norel X., Bäck M., Gascard J-P., Dahlen S. & Brink C. Pharmacological evidence for a novel cysteinyl-leukotriene receptor subtype in human pulmonary artery smooth muscle. Br. J. Pharmacol. 137:1339-1345. 2002.
  26. Bäck M, Norel X, Walch L, Gascard JP, Dahlen SE, Brink C. The contraction of the human pulmonary artery by LTC4 is resistant to cysLT1 antagonists and counteracted by prostacyclin release. Adv Exp Med Biol. 507:315-9, 2002.
  27. Walch L, Norel X, Gascard JP, Brink C. Leukotrienes and the pulmonary vascular bed. Adv Exp Med Biol. 507:309-13, 2002.
  28. Brink C, Dahlen SE, Drazen J, Evans JF, Hay DW, Nicosia S, Serhan CN, Shimizu T, Yokomizo T. International Union of Pharmacology XXXVII. Nomenclature for Leukotriene and Lipoxin Receptors. Pharmacol Rev. 55(1):195-227, 2003.
  29. Brink C, Dahlen SE, Drazen J, Evans JF, Hay DW, Rovati GE, Serhan CN, Shimizu T, Yokomizo T.  International Union of Pharmacology XLIV. Nomenclature for the oxoeicosanoid receptor. Pharmacol Rev.;56(1):149-57. 2004.
  30. Norel X, de Montpreville V, Brink C. Vasoconstriction induced by activation of EP1 and EP3 receptors in human lung: effects of ONO-AE-248, ONO-DI-004, ONO-8711 or ONO-8713. Prostaglandins Other Lipid Mediat. 74(1-4):101-12,2004.
  31. Norel X, Brink C. The quest for new cysteinyl-leukotriene and lipoxin receptors: recent clues. Pharmacol Ther.;103(1):81-94. 2004.
  32. Norel X, Walch L, Gascard JP, deMontpreville V, Brink C. Prostacyclin release and receptor activation: differential control of human pulmonary venous and arterial tone. Br J Pharmacol.; 142(4):788-96, 2004 .
  33. Chiang N, Serhan CN, Dahlen SE, Drazen JM, Hay DW, Rovati GE, Shimizu T, Yokomizo T, Brink C. The lipoxin receptor ALX: potent ligand-specific and stereoselective actions in vivo. Pharmacol Rev. ;58(3):463-87, 2006.
  34. Norel X. Prostanoid receptors in the human vascular wall. ScientificWorldJournal. 2007 Sep 1;7:1359-74. Review. PubMed PMID: 17767355.
  35. Kotelevets L, Foudi N, Louedec L, Couvelard A, Chastre E, Norel X. A new mRNA splice variant coding for the human EP3-I receptor isoform. Prostaglandins Leukot Essent Fatty Acids. 2007 Oct-Nov;77(3-4):195-201. Epub 2007 Nov 19. PubMed PMID: 18023986.
  36. Foudi N, Kotelevets L, Louedec L, Leséche G, Henin D, Chastre E, Norel X. Vasorelaxation induced by prostaglandin E2 in human pulmonary vein: role of the EP4 receptor subtype. Br J Pharmacol. 2008 Aug;154(8):1631-9. Epub 2008 Jun 2. PubMed PMID: 18516068; PubMed Central PMCID: PMC2518470.
  37. Foudi N, Louedec L, Cachina T, Brink C, Norel X. Selective cyclooxygenase-2 inhibition directly increases human vascular reactivity to norepinephrine during acute inflammation. Cardiovasc Res. 2009 Feb 1;81(2):269-77. Epub 2008 Oct 24. PubMed PMID: 18952694.
  38. Foudi N, Norel X, Rienzo M, Louedec L, Brink C, Michel JB, Bäck M. Altered reactivity to norepinephrine through COX-2 induction by vascular injury in hypercholesterolemic rabbits. Am J Physiol Heart Circ Physiol. 2009 Nov;297(5):H1882-8. Epub 2009 Sep 25. PubMed PMID: 19783781.
  39. Topal G, Foudi N, Uydes-Dogan BS, Cachina T, Kucur M, Gezer A, Madazli R, Ozdemir O, Norel X. Involvement of prostaglandin F2α in preeclamptic human umbilical vein vasospasm: a role of prostaglandin F and thromboxane A2 receptors. J Hypertens. 2010 Dec;28(12):2438-45. PubMed PMID: 20720498.
  40. Foudi N, Kotelevets L, Gomez I, Louedec L, Longrois D, Chastre E, Norel X. Differential reactivity of human mammary artery and saphenous vein to E(2) : Implication for cardiovascular grafts. Br J Pharmacol. 2011 prostaglandin Feb 16. doi: 10.1111/j.1476-5381.2011.01264.x. [Epub ahead of print] PubMed PMID: 21323896.
  41. Foudi N, Gomez I, Benyahia C, Longrois D, Norel X. Prostaglandin E2 receptor subtypes in human blood and vascular cells. Eur J Pharmacol. 2012 Nov 15;695(1-3):1-6. doi: 10.1016/j.ejphar.2012.08.009. Epub 2012 Sep 3. Review. PubMed PMID: 22964467.
  42. Longrois D, Gomez I, Foudi N, Topal G, Dhaouadi M, Kotelevets L, Chastre E, Norel X. Prostaglandin E2 induced contraction of human intercostal arteries is mediated by the EP₃ receptor. Eur J Pharmacol. 2012 Apr 15;681(1-3):55-9. doi: 10.1016/j.ejphar.2012.01.041. Epub 2012 Feb 12. PubMed PMID: 22342278.
  43. Benyahia C, Gomez I, Kanyinda L, Boukais K, Danel C, Leséche G, Longrois D, Norel X. PGE(2) receptor (EP(4)) agonists: potent dilators of human bronchi and future asthma therapy? Pulm Pharmacol Ther. 2012 Feb;25(1):115-8. doi: 10.1016/j.pupt.2011.12.012. Epub 2012 Jan 6. PubMed PMID: 22244823.
  44. Gomez I, Foudi N, Longrois D, Norel X. The role of prostaglandin E2 in human vascular inflammation. Prostaglandins Leukot Essent Fatty Acids. 2013 Aug;89(2-3):55-63. doi: 10.1016/j.plefa.2013.04.004. Epub 2013 Jun 4. Review. PubMed PMID: 23756023.
  45. Dagouassat M, Gagliolo JM, Chrusciel S, Bourin MC, Duprez C, Caramelle P, Boyer L, Hue S, Stern JB, Validire P, Longrois D, Norel X, Dubois-Randé JL, Le Gouvello S, Adnot S, Boczkowski J. The cyclooxygenase-2-prostaglandin E2 pathway maintains senescence of chronic obstructive pulmonary disease fibroblasts. Am J Respir Crit Care Med. 2013 Apr 1;187(7):703-14. doi: 10.1164/rccm.201208-1361OC. PubMed PMID: 23328527.
  46. Gomez I, Benyahia C, Le Dall J, Payré C, Louedec L, Leséche G, Lambeau G, Longrois D, Norel X. Absence of inflammatory conditions in human varicose saphenous veins. Inflamm Res. 2013 Mar;62(3):299-308. doi: 10.1007/s00011-012-0578-8. Epub 2012 Dec 13. PubMed PMID: 23238795.
  47. Topal G, Clària J, Norel X, Steinhilber D, Jakobsson PJ, Doğan SU, Bannenberg G. Editorial. Prostaglandins Other Lipid Mediat. 2015 Sep;121(Pt A):1-3. doi: 10.1016/j.prostaglandins.2015.11.001. PubMed PMID: 26686915.
  48. Gomez I, Ozen G, Deschildre C, Amgoud Y, Boubaya L, Gorenne I, Benyahia C, Roger T, Lesèche G, Galardon E, Topal G, Jacob MP, Longrois D, Norel X. Reverse Regulatory Pathway (H2S / PGE2 / MMP) in Human Aortic Aneurysm and Saphenous Vein Varicosity. PLoS One. 2016 Jun 30;11(6):e0158421. doi: 10.1371/journal.pone.0158421. eCollection 2016. PubMed PMID: 27362269; PubMed Central PMCID: PMC4928935.
  49. Lim AI, Li Y, Lopez-Lastra S, Stadhouders R, Paul F, Casrouge A, Serafini N, Puel A, Bustamante J, Surace L, Masse-Ranson G, David E, Strick-Marchand H, Le Bourhis L, Cocchi R, Topazio D, Graziano P, Muscarella LA, Rogge L, Norel X, Sallenave JM, Allez M, Graf T, Hendriks RW, Casanova JL, Amit I, Yssel H, Di Santo JP. Systemic Human ILC Precursors Provide a Substrate for Tissue ILC Differentiation. Cell. 2017 Mar 9;168(6):1086-1100.e10. doi: 10.1016/j.cell.2017.02.021. PubMed PMID: 28283063.
  50. Ozen G, Norel X. Prostanoids in the pathophysiology of human coronary artery. Prostaglandins Other Lipid Mediat. 2017 Mar 24. pii: S1098-8823(16)30160-5. doi: 10.1016/j.prostaglandins.2017.03.003. [Epub ahead of print] Review. PubMed PMID: 28347710.
  51. Foudi N, Ozen G, Amgoud Y, Louedec L, Choqueux C, Badi A, Kotelevets L, Chastre E, Longrois D, Norel X. Decreased vasorelaxation induced by iloprost during acute inflammation in human internal mammary artery. Eur J Pharmacol. 2017 Mar 31. pii: S0014-2999(17)30229-7. [Epub ahead of print] PubMed PMID: 28373136.


IgE Response

  1. Norel, X., Haye-Legrand, I., Labat, C., Benveniste, J. and Brink, C. Antigen contraction of IgE passively sensitized isolated human airway muscle preparations : role of prostaglandins and pharmacological modulation. Int. Archs. Allergy Appl. Imm. 96 : 368-375, 1991.
  2. Ortiz, J.L., Labat, C., Norel, X., Gorenne, I., Verley, J. and Brink, C. Histamine functional sites on human isolated pulmonary arterial muscle preparations: effects of endothelial cell removal and nitric oxide inhibitors. J. Pharmacol. Exp. Ther. 260: 762-767, 1992.
  3. Ortiz, J.L., Labat, C., Norel, X., Gorenne, I., Verley, J. and Brink, C. Response to human anti-IgE in human pulmonary arteries: regulation by endothelium. Am. Rev. Resp. Dis. 147: 1029-1033, 1993.
  4. Gorenne, I, Labat, C., Norel, X., Sosse Alaoui, H., Gascard, J.P. and Brink C. Anti-IgE response in human airways: relative contribution of inflammatory mediators. Mediators of Inflammation. 3: 359-363, 1994.
  5. Gorenne I, Labat C, Gascard JP, Brink C. Antigen stimulation of human pulmonary smooth muscle: an in vitro model of inflammation. Cell Biol Toxicol. 12(4-6):239-44, 1996.
  6. Gorenne, I., Labat, C., Norel, X., De Montpreville, V., Guillet, M.C., Cavero, I. and Brink, C. Beta-2-adrenoreceptor agonists effects on anti-IgE-induced contraction and smooth muscle reactivity in human airways. Br. J. Pharmacol. 114: 935-940, 1995.
Cholinergic control
  1. Norel, X., Angrisani, M., Labat, C., Gorenne, I., Dulmet, E., Rossi, F. and Brink, C. Degradation of acetylcholine in human airways: role of butyrylcholinesterase. Br. J. Pharmacol. 108: 914-919, 1993.
  2. Brink, C. The respiratory system. In: Aging of the Autonomic Nervous System. Ed. Amenta, CRC Press, Baton Rouge Florida, USA, pp. 194-212, 1993.
  3. Norel, X., Labat, C., De Santis, D., Gorenne, I., Dulmet, E., Rossi, F. and Brink, C. Cholinesterase inhibition by vecuronium and pancuronium in human airways. Life Sciences. 55 (14): PL261-PL266, 1994.
  4. Norel, X., Walch, L., Costantino, M., Labat, C., Gorenne, I., Dulmet, E., Rossi, F. and Brink, C. M1 and M3 muscarinic receptors in human pulmonary arteries. Br. J. Pharmacol. 119: 149-157, 1996.
  5. Costantino, M., Norel, X., Matera, M.G., Dulmet, E., Rossi, F. and Brink, C. Role of nitric oxide on cholinergic component of bronchial tone in pig. Pharmacol. Res. 34 (3/4): 157-160, 1996.
  6. Taisne, C., Norel, X., Walch, L., Labat, C., Verriest, C., Mazmanian, G.M. and Brink, C. Cholinesterase activity in pig airways and epithelial cells: effects of indomethacin. Fund. Clin. Pharmacol. 11: 201-205, 1997.
  7. Walch, L., Taisne, C., Gascard, J.P., Nashashibi, N., Brink, C. and Norel X. Cholinesterase activity in human pulmonary arteries and veins. Br. J. Pharmacol. 121: 986-990, 1997.
  8. Walch, L., Gascard, J.P., Leconte, B., Brink, C. and Norel X. Acetylcholine induces a greater production of prostacyclin in human pulmonary arteries than in veins. J. Physiol. Paris, 92: 507-508, 1998.
  9. Eum S.Y., Norel X., Lefort J., Labat C., Vargaftig B.B. & Brink C. Anaphylactic bronchoconstriction in BP2 mice: interactions between serotonin and acetylcholine. Br. J. Pharmacol., 126 (1), 312-316, 1999.
  10. Walch, L., Norel, X., Leconte, B., Gascard, J-P. and Brink C. Cholinergic control of human and animal pulmonary vascular tone. Thérapie. 54: 99-102, 1999.
  11. Walch L., Gascard J.P., Dulmet E., Brink C. & Norel X. Evidence for a M(1) muscarinic receptor on the endothelium of human pulmonary veins. Br. J. Pharmacol. 130(1), 73-78, 2000.
  12. Walch L, Brink C, Norel X.  The muscarinic receptor subtypes in human blood vessels. Therapie. 2001 56(3):223-6.
  13. Kotelevets L, Walch L, Chastre E, Chatonnet A, Dulmet E, Brink C, Norel X. Cholinesterase activity in human pulmonary arteries and veins: correlation with mRNA levels. Life Sci.;76(19):2211-20, 2005.
  14. Back M, Costantino M, Brink C, Norel X. Effect of cold storage on cholinergic responses induced by electrical field stimulation in human bronchi. Pulm Pharmacol Ther.; 19(4):297-302, 2006.